AI Portfolio Summary
In 2025 Q4, Paradigm Biocapital Advisors LP maintained a portfolio of 44 distinct positions. The most significant new addition to the portfolio was ORUKA THERAPEUTICS I, which now represents 1.32% of the total fund value. They heavily accumulated shares in REVOLUTION MEDICINES, increasing their position by 6.8%. Conversely, Paradigm Biocapital Advisors LP completely exited their position in AGIOS PHARMACEUTICAL.
Total Positions
44
Quarter
2025 Q4
Top Holding
NUVL (13.5%)
Top 10 Concentration
70.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-44 of 44
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NUVL
NUVALENT INC
|
Healthcare | 13.53% | 12.96% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
5,269,433 | $530,052,265 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 13.51% | 8.27% |
#2
2
Prev: #4
|
7.5 | 421,112 | 6.8% |
P
S
|
6,644,403 | $529,226,699 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
ARCELLX INC
|
Healthcare | 9.53% | 10.86% |
#3
Prev: #3
|
7.3 | 1,075,000 | 23.1% |
P
S
|
5,724,016 | $373,205,843 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GMAB
GENMAB A/S
|
Healthcare | 5.53% | 3.33% |
#4
4
Prev: #8
|
5.7 | 3,222,983 | 84.4% |
P
S
|
7,039,834 | $216,826,887 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 5.35% | 4.51% |
#5
Prev: #5
|
3.1 | -103,544 | -3.9% |
P
S
|
2,562,154 | $209,789,170 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 4.88% | 3.78% |
#6
1
Prev: #7
|
2.5 | -146,723 | -9.4% |
P
S
|
1,417,473 | $191,153,321 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 4.81% | 1.89% |
#7
10
Prev: #17
|
3.9 | 750,000 | 11.0% |
P
S
|
7,544,172 | $188,604,300 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 4.79% | 3.88% |
#8
2
Prev: #6
|
3.9 | 283,265 | 7.5% |
P
S
|
4,068,020 | $187,698,443 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 4.67% | 2.85% |
#9
2
Prev: #11
|
4.9 | 500,000 | 50.0% |
P
S
|
1,500,000 | $182,895,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
CIDARA THERAPEU...
|
Healthcare | 4.28% | 2.62% |
#10
3
Prev: #13
|
1.7 | -201,599 | -21.0% |
P
S
|
759,565 | $167,780,313 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 4.14% | 2.85% |
#11
1
Prev: #12
|
3.7 | 371,079 | 6.0% |
P
S
|
6,541,210 | $162,320,126 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRRK
SCHOLAR ROCK HL...
|
Healthcare | 3.44% | 2.13% |
#12
3
Prev: #15
|
4.4 | 1,052,412 | 52.4% |
P
S
|
3,062,157 | $134,888,016 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 2.67% | 2.39% |
#13
1
Prev: #14
|
3.1 | 257,564 | 6.1% |
P
S
|
4,473,648 | $104,772,836 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 2.63% | 3.02% |
#14
4
Prev: #10
|
1.6 | -340,000 | -13.3% |
P
S
|
2,210,774 | $102,911,530 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 2.16% | 1.72% |
#15
3
Prev: #18
|
0.9 | -398,514 | -26.2% |
P
S
|
1,123,243 | $84,782,382 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 1.72% | 0.81% |
#16
11
Prev: #27
|
3.7 | 1,686,110 | 84.1% |
P
S
|
3,691,475 | $67,443,248 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
ERASCA INC
|
Healthcare | 1.34% | 0.84% |
#17
9
Prev: #26
|
1.0 | 599,078 | 4.4% |
P
S
|
14,159,095 | $52,671,833 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 1.34% | 1.01% |
#18
7
Prev: #25
|
1.5 | no change | no change |
P
S
|
684,277 | $52,340,348 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.32% | — |
#19
Prev: #—
|
4.0 | 1,710,316 | no change |
NEW
|
1,710,316 | $51,839,678 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 1.23% | 0.70% |
#20
11
Prev: #31
|
1.5 | no change | no change |
P
S
|
1,467,266 | $48,067,634 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 1.21% | — |
#21
Prev: #—
|
4.0 | 4,763,198 | no change |
NEW
|
4,763,198 | $47,298,556 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 1.15% | 1.60% |
#22
3
Prev: #19
|
0.5 | -1,166,251 | -44.7% |
P
S
|
1,443,102 | $44,909,334 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 0.91% | 1.16% |
#23
1
Prev: #24
|
0.9 | -562,023 | -16.1% |
P
S
|
2,935,284 | $35,634,348 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 0.84% | — |
#24
Prev: #—
|
3.8 | 810,286 | no change |
NEW
|
810,286 | $32,735,554 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 0.72% | 0.61% |
#25
8
Prev: #33
|
2.8 | 395,608 | 21.2% |
P
S
|
2,261,749 | $28,317,097 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 0.58% | — |
#26
Prev: #—
|
3.7 | 1,750,000 | no change |
NEW
|
1,750,000 | $22,890,000 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASMB
ASSEMBLY BIOSCI...
|
Healthcare | 0.58% | — |
#27
Prev: #—
|
3.7 | 665,251 | no change |
NEW
|
665,251 | $22,625,187 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORIC
ORIC PHARMACEUT...
|
Healthcare | 0.50% | — |
#28
Prev: #—
|
3.7 | 2,401,217 | no change |
NEW
|
2,401,217 | $19,641,955 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVA
INVENTIVA SA
|
Healthcare | 0.47% | — |
#29
Prev: #—
|
3.7 | 4,000,000 | no change |
NEW
|
4,000,000 | $18,600,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KLRS
KALARIS THERAPE...
|
Healthcare | 0.15% | — |
#30
Prev: #—
|
3.6 | 700,000 | no change |
NEW
|
700,000 | $5,908,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
CALL
AGIOS PHARMACEU...
|
CALL Option | 0.00% | 0.23% |
Sold All 😨
(Was: #36) |
0.0 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.00% | 0.30% |
Sold All 😨
(Was: #35) |
0.0 | -372,869 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 0.00% | 0.47% |
Sold All 😨
(Was: #34) |
0.0 | -247,716 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 0.00% | 0.68% |
Sold All 😨
(Was: #32) |
0.0 | -1,898,950 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 0.00% | 0.73% |
Sold All 😨
(Was: #30) |
0.0 | -1,900,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 0.00% | 0.74% |
Sold All 😨
(Was: #29) |
0.0 | -3,086,184 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
CALL
MERUS N V
|
CALL Option | 0.00% | 0.80% |
Sold All 😨
(Was: #28) |
0.0 | -300,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 0.00% | 1.29% |
Sold All 😨
(Was: #23) |
0.0 | -3,156,398 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 0.00% | 1.30% |
Sold All 😨
(Was: #22) |
0.0 | -1,835,494 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LENZ
LENZ THERAPEUTI...
|
Healthcare | 0.00% | 1.42% |
Sold All 😨
(Was: #21) |
0.0 | -1,073,461 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 0.00% | 1.47% |
Sold All 😨
(Was: #20) |
0.0 | -1,719,334 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JANX
JANUX THERAPEUT...
|
Healthcare | 0.00% | 2.03% |
Sold All 😨
(Was: #16) |
0.0 | -2,920,258 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
AGIOS PHARMACEU...
|
Healthcare | 0.00% | 3.05% |
Sold All 😨
(Was: #9) |
0.0 | -2,673,555 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
MERUS N V
|
Healthcare | 0.00% | 11.71% |
Sold All 😨
(Was: #2) |
0.0 | -4,373,770 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-44 of 44 holdings